NTrans Technologies today announced it has been awarded a prestigious, €1.5M EU SME instrument grant. NTrans Technologies is a spin-off company that emerged from research of the Hubrecht Institute. The company is based on a proprietary technology (iTOP), which allows the intracellular delivery of therapeutic proteins in a wide range

NTrans Technologies wins the AXON Innovation for Health Award 2017 On Thursday 16 February during the fourth edition of the annual Innovation for Health conference in WTC Rotterdam, Marco de Boer of NTrans Technologies won the AXON Innovation for Health Award 2017 for the best innovation pitch presentation. NTrans Technologies

Cell 161(3):674-690 · April 2015 Modulation of protein function is used to intervene in cellular processes but is often done indirectly by means of introducing DNA or mRNA encoding the effector protein. Thus far, direct intracellular delivery of proteins has remained challenging. We developed a method termed iTOP, for induced